A new medicine and two imaging agents have been recommended for marketing in Europe under the European Union’s conditional licensing procedure – a procedure that enables medicines to reach patients on the basis of a limited data package.
Horizon Discovery Group Plc has raised £68.6 million with an initial public offering on the London Stock Exchange’s Alternative Investment Market, well in excess of the originally targeted £25 million. Horizon will use the funds to expand the sales of its genomics research tools.
Evotec AG has announced the acquisition of a small asset management company, Bionamics GmbH, to help it accelerate the translation of academic innovations into assets for the biotech and pharmaceutical industry. Financial terms weren’t disclosed.
Zealand Pharma A/S had revenue of DKK 6.6 million (€0.9 million) for 2013, wholly made up of royalty payments on sales of its first marketed product, Lyxumia (lixisenatide), for Type 2 diabetes. Revenue in 2012 was DKK 223.6 million and milestone based.
The European Medicines Agency is inviting pharmaceutical companies to participate in a pilot project under which it will evaluate ‘adaptive licensing’ as a way of getting new medicines to patients earlier, under certain controlled situations.
A Phase 3 trial of a MAGE-A3 cancer vaccine has failed to significantly extend disease-free survival in patients with non-small lung cancer – the first and second co-primary endpoints, according to the developer GlaxoSmithKline Plc.
The UK government has decided to commit £55 million for the construction of a cell therapy manufacturing centre to support the commercialization of cell therapies, attract inward investment, and boost exports. The investment was announced on 19 March.
Bristol-Myers Squibb Company is set to gain access to new targets for the development of checkpoint inhibitors against cancer under a licensing deal with Five Prime Therapeutics Inc carrying an upfront payment of $20 million.
A Phase IV study of bosentan has failed to show that the drug significantly prolongs time to first morbidity or mortality in patients with pulmonary arterial hypertension (PAH) already receiving sildenafil. Bosentan (Tracleer) is marketed by Actelion Pharmaceuticals Ltd.
BioInvent International AB, which is developing three antibodies to treat cancer, plans to raise SEK 48.9 million (€5.5 million) with a rights offering on the NASDAQ OMX Exchange in Stockholm. The proceeds will support the company’s ongoing research.